Vera, R.
Castro, N.
Labiano, I.
Lecumberri, A.
Huerta, A. E.
Arasanz, H.
Caseda, I.
Ruiz-Pace, F.
Viaplana, C.
Arrazubi, V.
Hernandez-Garcia, I.
Mata, E.
Gomez, D.
Laguna, S.
Suarez, J.
Fernandez-De-los-Reyes, I.
Rullan, M.
Estremera, F.
Alonso, V.
Pazo-Cid, R.
Gil-Negrete, A.
Lafuente, A.
Martin-Carnicero, A.
Dientsmann, R.
Alsina, M.
Funding for this research was provided by:
Agencia Estatal de Investigación (8FJC2021-046521-I)
Fundación Científica Asociación Española Contra el Cáncer (CLJUN234885LECU, CLJUN19010ARAS, AECC SEED IDEAS 2023)
Ministerio de Ciencia, Innovación y Universidades (Knowledge Generation Proyects 2022)
Departamento de Salud, Gobierno de Navarra (La Caixa Program)
Article History
Received: 12 February 2024
Accepted: 30 May 2024
First Online: 1 June 2024
Declarations
:
: Ethics Committee for Investigation with medicinal products from Navarra, have approved this project with the following record ID, CI_2023/144. This collection has been included in to the National Institute of Health Carlos III (ISCIII) registry with the following reference, C.0008110.
: Not applicable.
: RV has been involved as a consultant for advisory roles with Servier, Roche and Merck Sharp and has received speaker honoraria from Roche, Amgen, Merck Sharp and Dohme, Astra Zeneca. IL, NC, AEH, IC, FRP, CV, DG, JS, IFR, MR, FE, AGN, AL, VA, RPC and SL declare no conflict of interest. AL has received speaker honoraria from Pierre-Fabre. HA has been involved as a consultant for advisory roles from Astra Zeneca and for trial coordination from Ferrer Farma and received speaker honoraria from Takeda. VA has been involved as a consultant for advisory roles and received speaker honoraria from MSD, Bristol, Lilly, Astra-Zeneca and Pierre-Fabre. IHG has received speaker honoraria from Astra Zeneca. EM has been involved as a consultant for advisory roles with Servier, Roche and Merck Sharp and Dohme. RD declares advisory role for Roche, Foundation Medicine, received a speaker’s fee from Roche, Ipsen, Amgen, Servier, Sanofi, Libbs, Merck Sharp & Dohme, Lilly, AstraZeneca, Janssen, Takeda, Bristol Myers Squibb, GlaxoSmithKline, Gilead, research grants from Merck, Novartis, Daiichi-Sankyo, GlaxoSmithKline and AstraZeneca, and is investor in Trialing Health, S.L. AMC declares advisory role for Servier, Novartis, Pharmamar and Bristol Myers Squibb, received speaker honoraria from Novartis, Roche, Merck Sharp and Dohme, Merck, Pierre Fabre, Amgen, Sanofi, Servier and Bristol Myers Squib. MA has been involved as a consultant for advisory roles with Amgen, BMS, MSD, Lilly and Servier.